A Phase 2, Open-Label, Randomized Comparative Effectiveness Study for MDMA-Assisted Therapy in U.S. Military Veterans with Chronic PTSD Timeline

Enrolling: Phase 2 Study at the Bronx, New York Veterans Affairs Medical Center

September 21, 2022
Five Participants Enrolled in Phase 2 Study at the Bronx, New York Veterans Affairs Medical Center

August 8, 2022
First Participant Completes Treatment in Phase 2 Study at the Bronx, New York Veterans Affairs Medical Center

July 19, 2022
One Subject Treated, Four Subjects Evaluated in Phase 2, Open-Label, Randomized Comparative Effectiveness Study for MDMA-Assisted Therapy in U.S. Military Veterans with Chronic PTSD

May 4, 2022
Participant Enrolled in Phase 2, Open-Label, Randomized Comparative Effectiveness Study for MDMA-Assisted Therapy in U.S. Military Veterans with Chronic PTSD

April 15, 2022
First Participant Treated in A Phase 2, Open-Label, Randomized Comparative Effectiveness Study for MDMA-Assisted Therapy in U.S. Military Veterans with Chronic PTSD

February 3, 2022
First Participant Will Enroll in A Phase 2, Open-Label, Randomized Comparative Effectiveness Study for MDMA-Assisted Therapy in U.S. Military Veterans with Chronic PTSD

January 24, 2022
First Participant Screening in A Phase 2, Open-Label, Randomized Comparative Effectiveness Study for MDMA-Assisted Therapy in U.S. Military Veterans with Chronic PTSD

December 15, 2021
First Participant Consented to Participation in A Phase 2, Open-Label, Randomized Comparative Effectiveness Study for MDMA-Assisted Psychotherapy in U.S. Military Veterans with Chronic PTSD

November 23, 2021
Site Initiation Visit Takes Place for Phase 2 Study at the Veterans Affairs Medical Center in Bronx, New York

September 22, 2021